Selected Publications
Nasioudis D, Wang X, Dhillon G, Latif N, Ko EM, Giuntoli RL 2nd, Gershenson D, Fader A, Carey M, Simpkins F.: Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery. Int J Gynecol Cancer. : 33(12):1906-1912. doi: 10.1136/ijgc-2023-004745.,2023.
Andriani L, Oh J, McMinn E, Gleason E, Koelper NC, Chittams J, Simpkins F, Ko EM.: Telehealth utilization in gynecologic oncology clinical trials. Gynecol Oncol. : 177:103-108. doi: 10.1016/j.ygyno.2023.08.011,2023.
Nasioudis D, Fernandez ML, Wong N, Powell DJ Jr, Mills GB, Westin S, Fader AN, Carey MS, Simpkins F.: The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches. Gynecol Oncol. : 177:86-94. doi: 10.1016/j.ygyno.2023.08.007,2023.
Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D'Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, Schwartz LE, Hwang WT, Nathanson KL, Mills GB, Velculescu VE, Wang TL, Brown EJ, Drapkin R, Simpkins F.: Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer. Res Sq. : 27:rs.3.rs-3314138. doi: 10.21203/rs.3.rs-3314138/v1.,2023.
Smith AJB, Alvarez R, Heintz J, Simpkins F, Ko EM.: Disparities in clinical trial participation in ovarian cancer: A real-world analysis.
Gynecol Oncol. : 175:25-31. doi: 10.1016/j.ygyno.2023.05.066.,2023.
Nasioudis D, Latif NA, Ko EM, Cory L, Kim SH, Martin L, Simpkins F, Giuntoli R 2nd.: Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma. Gynecol Oncol. : 177:14-19,2023.
Gitto SB, Whicker M, Davies G, Kumar S, Kinneer K, Lewis A, Mamidi S, Medvedev S, Anderton J, Tang J, Ferman B, Coats S, Wilkinson RW, Brown, E, Powell Jr. DJ, Simpkins F.: A B7-H4 targeting antibody-drug conjugate shows anti-tumor activity in PARPi and platinum resistant cancers with B7-H4 expression. Clinical Cancer Research, accepted. : 2023.
Bauer TM, Moore KN, Rader JS, Simpkins F, Mita AC, Beck JT, Hart L, Chu Q, Oza A, Tinker AV, Imedio ER, Kumar S, Mugundu G, Jenkins S, Chmielecki J, Jones S, Spigel D, Fu S.: A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors Target Oncol. : 18(4):517-530,2023.
Pantel AR, Gitto SB, Makvandi M, Kim H, Medvedv S, Weeks JK, Torigian DA, Hsieh CJ, Ferman B, Latif NA, Tanyi JL, Martin LP, Lanzo SM, Liu F, Cao Q, Mills GB, Doot RK, Mankoff DA, Mach RH, Lin LL, Simpkins F.: [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study Clin Cancer Res : 29(8):1515-1527. doi: 10.1158/1078-0432.CCR-22-1602,2023.
Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, Armstrong DK, Gaillard S, Giuntoli R, Simpkins F: Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer Clin Cancer Res : CCR-22-2444. doi: 10.1158/1078-0432.CCR-22-2444,2023.
Academic Contact Information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia,
PA
19104
Phone: 215-662-3318
Patient appointments: 800-789-7366